Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Outcome of Stem Cell Transplantation in Adults with Acute Myelogenous Leukemia and Normal Cytogenetics (NC-AML) According to Presence of FLT-3 Internal Tandem Duplication (FLT-3ITD) At the Time of Diagnosis

Ellin Berman, MD, Ann A Jakubowski, MD, PhD, Molly Maloy, BA, Joseph G. Jurcic, MD, Suresh C. Jhanwar, PhD, Cyrus V. Hedvat, MD, PhD, Sergio Giralt, MD, Esperanza B. Papadopoulos, MD

Blood (2012) 120 (21): 2038.

https://doi.org/10.1182/blood.V120.21.2038.2038

Published: 2012

Journal Articles

Influence of National Comprehensive Cancer Network (NCCN) Guidelines on Clinical Practice in Patients with Chronic Myelogenous Leukemia (CML) Treated At a Single Academic Medical Center

Ellin Berman, MD, Cyrus V. Hedvat, MD, PhD, Joseph G. Jurcic, MD, Mark Heaney, MD, PhD, Peter G. Maslak, M.D., Renier Brentjens, MD, PhD, Nicole Lamanna, MD, Todd L. Rosenblat, MD, Mark G. Frattini, MD, PhD, Ann A Jakubowski, MD, PhD, Suresh Jhanwar, PhD

Blood (2011) 118 (21): 4433.

https://doi.org/10.1182/blood.V118.21.4433.4433

Published: 2011

Journal Articles

Clinical Outcomes In Patients with Chronic Myelogenous Leukemia (CML) and the BCR-ABL 35 Base Pair (bp) Intron 8 Insertion Mutation.

Ellin Berman, MD, Jorge Cortes, MD, Hagop M. Kantarjian, MD, Thomas O'Hare, PhD, Christopher Eide, BS, Richard D. Press, MD, PhD, Brian J Druker, MD, Cyrus V. Hedvat, MD, PhD

Blood (2010) 116 (21): 3408.

https://doi.org/10.1182/blood.V116.21.3408.3408

Published: 2010

Journal Articles

Low Proliferation Index May Be Associated with Longer Time to First Therapy In Low Grade Follicular Lymphoma

Meirav Kedmi, MD, Cyrus V. Hedvat, MD, PhD, Jocelyn Maragulia, Andrew D Zelenetz, MD

Blood (2010) 116 (21): 4149.

https://doi.org/10.1182/blood.V116.21.4149.4149

Published: 2010

Journal Articles

Prognostic Significance of Positron Emission Tomography (FDG-PET) at Baseline and After 4 Cycles of R-CHOP in 75 Patients with Mantle Cell Lymphoma Treated with Intensive Chemotherapy and Autologous Stem Cell Rescue.

Rony Schaffel, MD, PhD, Craig H. Moskowitz, MD, Jocelyn C. Maragulia, Carol S. Portlock, MD, Cyrus V. Hedvat, MD, PhD, Andrew D. Zelenetz, MD, PhD

Blood (2009) 114 (22): 1226.

https://doi.org/10.1182/blood.V114.22.1226.1226

Published: 2009

Journal Articles

TET2 and ASXL1 Mutations in Leukemic Transformation of Chronic Myeloproliferative Neoplasms.

Omar Abdel-Wahab, Taghi Manshouri, Jay Patel, Kelly Harris, Jin Juan Yao, MD, PhD, Cyrus V. Hedvat, MD, PhD, Adriana Heguy, Carlos Bueso-Ramos, Hagop M. Kantarjian, MD, Ross L. Levine, MD, Srdan Verstovsek, MD, PhD

Blood (2009) 114 (22): 2894.

https://doi.org/10.1182/blood.V114.22.2894.2894

Published: 2009

Journal Articles

Efficacy of the Novel Non-Quinone Based HSP-90 Inhibitor PU-H71 in JAK2V617F and MPLW515L-Induced Murine Models of Myeloproliferative Neoplasms.

Priya Koppikar, PhD, Sachie Marubayashi, Tony Taldone, Omar Abdel-Wahab, Nathan West, Alexander Gozman, James Ahn, Anna Rodina, Neha Bhagwat, Cyrus V. Hedvat, MD, PhD, James E. Bradner, MD, Gabriela Chiosis, Ross L. Levine, MD

Blood (2009) 114 (22): 3898.

https://doi.org/10.1182/blood.V114.22.3898.3898

Published: 2009

Journal Articles

Akt-Mediated Phosphorylation of Bmi1 Regulates Its Chromatin Association and Growth Promoting Properties.

Yan Liu, Fan Liu, Ph.D., Xinyang Zhao, Goro Sashida, Anthony Deblasio, Zhenbang Chen, Hui-kuan Lin, Silvana Di Giandomenico, Shannon Elf, Youyang Yang, Yasuhiko Miyata, MD, PhD, Gang Huang, Ph.D., Silvia Menendez, Ingo Mellinghoff, MD, Pier Paolo Pandolfi, MD, PhD, Cyrus V. Hedvat, MD, PhD, Stephen D. Nimer

Blood (2009) 114 (22): 3605.

https://doi.org/10.1182/blood.V114.22.3605.3605

Published: 2009

Journal Articles

The Serum Free Light Chain Ratio after One or Two Cycles of Treatment Is Highly Predictive of the Magnitude of Final Response in Patients Undergoing Initial Treatment for Multiple Myeloma.

Hani Hassoun, MD, Lilian Reich, MD, Virginia M. Klimek, MD, Madhav Dhodapkar, MD, Adam Cohen, MD, Tarun Kewalramani, MD, Elyn R. Riedel, MA, Cyrus V. Hedvat, MD, Julie Teruya-Feldstein, MD, Daniel A. Filippa, MD, Martin Fleisher, PhD, Stephen D. Nimer, MD, Raymond L. Comenzo, MD

Blood (2005) 106 (11): 3481.

https://doi.org/10.1182/blood.V106.11.3481.3481

Published: 2005

Journal Articles

Doxorubicin and Dexamethasone Followed by Thalidomide and Dexamethasone (AD-TD) as Initial Therapy for Symptomatic Patients with Multiple Myeloma.

Hani Hassoun, MD, Lilian Reich, MD, Virginia M. Klimek, MD, Tarun Kewalramani, MD, Madhav Dhodapkar, MD, Lisa Drake, Rachel Zimman, Cyrus V. Hedvat, MD, Teruya-Feldstein Julie, MD, Fleisher Martin, phD, Daniel A. Filippa, MD, Stephen D. Nimer, MD, Raymond L. Comenzo, MD

Blood (2004) 104 (11): 2409.

https://doi.org/10.1182/blood.V104.11.2409.2409

Published: 2004

NARROW

Outcome of Stem Cell Transplantation in Adults with Acute Myelogenous Leukemia and Normal Cytogenetics (NC-AML) According to Presence of FLT-3 Internal Tandem Duplication (FLT-3ITD) At the Time of Diagnosis

Influence of National Comprehensive Cancer Network (NCCN) Guidelines on Clinical Practice in Patients with Chronic Myelogenous Leukemia (CML) Treated At a Single Academic Medical Center

Clinical Outcomes In Patients with Chronic Myelogenous Leukemia (CML) and the BCR-ABL 35 Base Pair (bp) Intron 8 Insertion Mutation.

Low Proliferation Index May Be Associated with Longer Time to First Therapy In Low Grade Follicular Lymphoma

Prognostic Significance of Positron Emission Tomography (FDG-PET) at Baseline and After 4 Cycles of R-CHOP in 75 Patients with Mantle Cell Lymphoma Treated with Intensive Chemotherapy and Autologous Stem Cell Rescue.

TET2 and ASXL1 Mutations in Leukemic Transformation of Chronic Myeloproliferative Neoplasms.

Efficacy of the Novel Non-Quinone Based HSP-90 Inhibitor PU-H71 in JAK2V617F and MPLW515L-Induced Murine Models of Myeloproliferative Neoplasms.

Akt-Mediated Phosphorylation of Bmi1 Regulates Its Chromatin Association and Growth Promoting Properties.

The Serum Free Light Chain Ratio after One or Two Cycles of Treatment Is Highly Predictive of the Magnitude of Final Response in Patients Undergoing Initial Treatment for Multiple Myeloma.

Doxorubicin and Dexamethasone Followed by Thalidomide and Dexamethasone (AD-TD) as Initial Therapy for Symptomatic Patients with Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only